Navigation Links
My Vision Express Software

ProductsMy Vision Express Software
Company Insight Software, LLC.
Item My Vision Express Software
Features My Vision Express is a true Client-Server application and supports unlimited number of computers. There is No additional fees per computer or users and works on all Windows operating systems. It includes FREE support and FREE updates for one year from the date of purchase.
Description My Vision Express is a powerful, fully automated information and data processing system that will raise productivity, reduce errors, increase profitability, and all at a very affordable price. My Vision Express program has been designed and developed as an eye care business management and point of purchase software. This fully integrated software is extremely user friendly allowing all personnel to be trained in a short period of time.
Info Insight Software, LLC.
Customer Service: (877) 882-7456
Web site: http://www.myvisionexpress.com

Related medicine products :

1. Optec 3500 Vision Tester
2. Optec Vision Tester
3. Vision Monitor Visual electrophysiology
4. VisionBlue
5. PVA, The Personal Vision Assistant
6. Welch Allyn Suresight™ Vision Screener (English)
7. SheerVision Surgical Magnifying Loupes
8. Visions PV 018
9. Multi-Link Vision OTW
10. Multi-Link Vision RX
11. In-Vision Gold Intravascular Ultrasound System (IVG3)
Pre-Loaded with a Stylet., ,Available Cuffed or Uncuffed, pre-loaded with a stylet to facilitate quick intubations.
Worlds 1st spray on medical gel lubricant, Sprayglyde was specifically designed to assist the insertion of laryngeal masks.
Pediatric Tracheal Tubes with Micro-thin-walled cuffs.
Indications For Usage: , Emergency use. , When medicant during ventilation is required.
Medicine Products:
(Date:5/16/2008)...o Save Vital Services for Frail Seniors and People...wswire-USNewswire/ -- Thousands of,homecare worker...warzenegger,s proposed cuts to hours of service, w...ornia,s most vulnerable workers and the,people the...these vital,services for seniors and people with d...
(Date:5/16/2008)...sents Urban Health Institute with 10,000 Sensual O...rg at Playboy Mansion Fundraiser, LOS ANGELES, Ma...ip-hop,and R & B artist J Kwon known best for his ...ll be presenting the Urban Health Institute (UHI) ... over $50,000. The donation is,being made to promo...
(Date:5/16/2008)...docs determine who would benefit most from chemo a... 16 (HealthDay News) -- A panel of 15 genes may he...mall cell lung cancer will experience a recurrence...y, a new study shows. , By extension, the same... less aggressive forms of the cancer who would be ...
(Date:5/16/2008)...TON, May 16 /PRNewswire-USNewswire/ -- As tropical...e Irrawaddy delta, survivors of,Cyclone Nargis are... Many,survivors still need assistance, as exposure... an increasingly dire situation., "The people liv...,recover from this disaster and get back on their ...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
...dually increased recommendations for daily calcium...00 and 1,300 milligrams // to promote healthy bone... in a medical journal said boosting consumption of... the best way to provide the minimal calcium intak...
...ering from the most common form of brain cancer mi... and // chemotherapy than radiotherapy alone . Bas...people with the type of cancer known as glioblasto...the cancer as safely possible and then undergo rad...
... the opinion that dairy products provide the neces...n a study conducted recently on collected informat...hildren and adolescence and consumption of dairy p...p between the two. Children are often advised to t...
...ted at American College of Cardiology, laughter ca...ef presenter of the paper Michael Miller, MD, dire...ssociate professor of medicine at the University o...ion after studying 300 participants, 150 healthy a...
Other Medicine News:
(Date:5/16/2008)...ata from three studies,evaluating associations bet...d the rate of blood transfusions, as well as the p...r erythropoiesis-stimulating agents (ESAs),in Medi...e presented at the,American Society of Clinical On... meeting will take place in Chicago from May 30 to...
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Hospital Launches Landmark Project in Emergency Medicine 9268 1Hospital Launches Landmark Project in Emergency Medicine 9268 2Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 1Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 1International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 3International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 4International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 5Other highlights in the Jan 8 JNCI 9262 1Other highlights in the Jan 8 JNCI 9262 2Other highlights in the Jan 8 JNCI 9262 3Other highlights in the Jan 8 JNCI 9262 4
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
...bjective Sleep,Measures, MINNEAPOLIS, June 13, 200...ults presented today at SLEEP 2007, the 21st annua...ieties (APSS),VEC-162, a balanced melatonin (MT1/...rmaceuticals Inc. , demonstrated improvements,in o...d maintenance,in a Phase III trial of transient in...
Other Medicine Technology:Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 2Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 3Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 4